This trial is testing a new cancer treatment that uses two drugs, pembrolizumab and vibostolimab, in combination with standard chemotherapy and radiation therapy. The new treatment is being compared to standard chemotherapy and radiation therapy followed by a different drug, durvalumab. The primary hypotheses are that the new treatment will improve progression-free survival and overall survival in patients with non-small cell lung cancer.
4 Primary · 26 Secondary · Reporting Duration: Up to approximately 75 months
2 Treatment Groups
1 of 2
1 of 2
784 Total Participants · 2 Treatment Groups
Primary Treatment: pembrolizumab/vibostolimab · No Placebo Group · Phase 3
Who is running the clinical trial?
Age 18+ · All Participants · 11 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
- 2022. "Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006/KEYVIBE-006)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05298423.
Frequently Asked Questions
Do pembrolizumab/vibostolimab have any long-term side effects?
"Pembrolizumab/vibostolimab's safety is estimated to be a 3. This comes from it being a Phase 3 trial, which has some data supporting efficacy and multiple rounds of safety data." - Anonymous Online Contributor
Are we able to sign up for this testing program at the present moment?
"That is correct, the online clinicaltrials.gov database has that this study, which was first posted on May 3rd 2022, presently recruiting participants. The research team hopes to enroll 784 patients from 7 different locations." - Anonymous Online Contributor